HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Clinical trials for HR-POSITIVE, HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR-POSITIVE, HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HR-POSITIVE, HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New radioactive drug targets FAP-Positive tumors in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New radiation 'Smart Bomb' targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could a simple hormone test spare thousands of women from chemo?
Disease control Recruiting nowThis phase 3 trial is testing whether premenopausal women with a common type of breast cancer (HR+/HER2-) can safely skip chemotherapy if their tumor responds well to hormone therapy before surgery. About 950 women will be randomly assigned to either standard surgery first or hor…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Tokyo Women's Medical University • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for breast cancer patients: experimental drug combo enters Mid-Stage trial
Disease control Recruiting nowThis phase 2 trial tests whether a new drug called culmerciclib, combined with fulvestrant, works better than standard CDK4/6 inhibitors plus fulvestrant for people with HR-positive, HER2-negative breast cancer that has worsened after first-line hormone therapy. About 98 women ag…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug cocktail aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis study is testing whether adding an immunotherapy drug called QL1706 to standard chemotherapy before surgery can improve outcomes for people with HR-positive, HER2-negative breast cancer. About 55 participants will receive the combination, and researchers will measure how man…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC